GPCR compared with ARWR: revenue, margins and what each company keeps, and the suppliers and customers both name

GPCRStructure Therapeutics Inc.

Mkt capRevenueRevenue

ARWRArrowhead Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

GPCRStructure Therapeutics Inc.

ARWRArrowhead Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

GPCR

No earnings history for GPCR.

ARWR

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±8.5%▼−2.99%×0.35

Q2 FY26±7.3%▼−6.75%×0.93

Q1 FY26±11.4%▼−0.19%×0.02

Nov 26 '25±13.6%▲+23.34%×1.71

= impliedGPCR realized, solidARWR realized, hatchedOne scale, both sides: full bar = 24%× = |realized| ÷ impliedSource: market data

GPCRStructure Therapeutics Inc.

21.89· pre 22.01

Mkt cap$4.8BRevenue—Revenue—

ARWRArrowhead Pharmaceuticals, Inc.

60.49· pre 59.64· delayed

Pre-marketSep 2 '83

Mkt cap$8.5BRevenue$75MQ3 FY26Revenue$829MFY25

Compare

Pre-marketSep 2 '83

GPCRStructure Therapeutics Inc.

ARWRArrowhead Pharmaceuticals, Inc.

21.89pre 22.01

Price

60.49pre 59.64delayed

$4.8B

Mkt cap

$8.5B

—

Revenue

$75MQ3 FY26

—

Revenue

$829MFY25

GPCR21.89vsARWR60.49Pre-marketSep 2 '83